 |
|
|
| |
Sofosbuvir Plus Ribavirin for the Treatment of Russian Patients With Chronic HCV Genotype 1 or 3 Infection
|
| |
| |
Reported by Jules Levin
APASL 2015
March 12-15, Istanbul, Turkey
Konstantin Zhdanov1, Vasily Isakov2, Kathryn Kersey3, Yanni Zhu3, Evguenia Svarovskaia3, Benedetta Massetto3, Sergey Zhuravel4, Svetlana Romanova5, Elena Nurmukhametova6, Viacheslav Morozov7, Galina Kozhevnikova8, Larisa Gogova9, Natalia Geyvandova10, Natalia Gankina11, Evgenii Chesnokov12, Eduard Burnevich13, Elena Bessonova14, Djamal Abdurakhmanov15, Diana M. Brainard3, John G. McHutchison3, Vladimir Chulanov8, Igor G. Bakulin16
1Military Medical Academy, St Petersburg, Russian Federation; 2Institute of Nutrition of Russian Academy of Medical Sciences, Moscow, Russian Federation 3Gilead Sciences, Inc., Foster City, CA, USA; 4Scientific Research Institute of Emergency Care n.a. N.V. Sclifosovskiy of Healthcare Department of Moscow, Moscow, Russian Federation; 5Center for Prevention and Control of AIDS and Infectious Diseases, St Petersburg, Russian Federation; 6Infectious Clinical Hospital 1 of Moscow Healthcare Department, Moscow, Russian Federation; 7Medical Company Hepatolog, LLC, Samara, Russian Federation; 8Central Research Institute of Epidemiology, Moscow, Russian Federation; 9Central Clinical Hospital of the Russian Academy of Sciences, Moscow, Russian Federation; 10Stavropol Regional Clinical Center of Special Medical Care, Stavropol, Russian Federation; 11Krasnoyarsk Regional Center for Prevention and Control of AIDS and Infectious Diseases, Krasnoyarsk, Russian Federation; 12Consultation and Diagnostic Centre, Tymen, Russian Federation; 13City Clinical Hospital 24, Moscow, Russian Federation; 14Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation; 15IM Sechenov First Moscow State Medical University, Moscow, Russian Federation; 16Moscow Central Scientific Institute of Gastroenterology, Moscow, Russian Federation
|
| |
|
|
|
|
|
